CYP2A6 and lung cancer: CYP2A6 genetic variants are important to consider clinically because there are negative outcomes associated with higher rates of nicotine metabolism, including increased tobacco consumption, more difficulty with smoking cessation, poorer success with nicotine replacement therapy and elevated risk of lung cancer [27,75,79].